Delving into the Latest Updates on iNTS-GMMA vaccine with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, OMV vaccine

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious Diseases

Active Indication

Salmonella Infections

Inactive Indication-

Originator Organization

GSK Plc

Active Organization

GSK Plc

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

A Phase IIa Observer-blind, Randomized, Controlled, Age-de-escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, Including Dose-finding in Infants, in Africa

The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-generalized modules for membrane antigens (iNTS-GMMA) candidate vaccine against S. Typhimurium and S. Enteritidis with an age de-escalation and dose escalation approach in African population, starting with adults (18-50 years of age), then on children (24-59 months of age) and finally to infants (9 months and 6 weeks of age). Infants are the target for primary vaccination from 6 weeks of age.

Start Date15 Jan 2024

Sponsor / Collaborator

GSK Plc

[+2]

100 Clinical Results associated with iNTS-GMMA vaccine

Login to view more data

100 Translational Medicine associated with iNTS-GMMA vaccine

Login to view more data

100 Patents (Medical) associated with iNTS-GMMA vaccine

Login to view more data

100 Deals associated with iNTS-GMMA vaccine

Login to view more data